General Information of the Drug (ID: M6APDG03710)
Name
ISIS 133208
Status
Investigative
TTD Drug ID
D09PFL
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
DUSP5 messenger RNA (DUSP5 mRNA)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary DUSP5 messenger RNA (DUSP5 mRNA) is a therapeutic target for ISIS 133208. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 133208 through regulating the expression of DUSP5 messenger RNA (DUSP5 mRNA). [1], [2]
References
Ref 1 METTL3-mediated N6-methyladenosine modification of DUSP5 mRNA promotes gallbladder-cancer progression. Cancer Gene Ther. 2022 Jul;29(7):1012-1020. doi: 10.1038/s41417-021-00406-5. Epub 2021 Nov 19.
Ref 2 US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression.